BH CORRESPONDENT, New Delhi: Adar Poonawalla, the CEO of the Serum Institute of India, which is conducting trials of COVID-19 vaccine, took to Twitter to highlight challenges in vaccine production and distribution in India.
“Quick question: will the Government of India have 80,000 crores available over the next one year? Because that is what the Ministry of Health needs to buy and distribute the vaccine to everyone in India. This is the next concerning challenge we need to tackle,” Poonawalla tweeted.
Then, he quickly followed it up with another tweet where he said that he is asking the question because as vaccine manufactures they need to plan and guide in terms of procurement and distribution.
“I ask this question, because we need to plan and guide, vaccine manufacturers both in India and overseas to service the needs of our country in terms of procurement and distribution,” he tweeted.
I ask this question, because we need to plan and guide, vaccine manufacturers both in India and overseas to service the needs of our country in terms of procurement and distribution.
— Adar Poonawalla (@adarpoonawalla) September 26, 2020
Covishield is a vaccine developed by the University of Oxford and AstraZeneca and being tested by the Serum Institute of India in the country. The vaccine is currently in Phase 2 and Phase 3 human trials.